Making Strides in Reimbursement, Digital Innovation, and Community
It's hard to believe that we're already halfway through 2023. As we head into the second half of the year, I wanted to take a moment to reflect on some of our recent wins at Journey Biosciences.?
One of the most exciting things is our progress on the reimbursement front. We received our CPT code earlier this year and crossed a major milestone in the reimbursement process. Our focus is now on creating access for NaviDKD with CMS and health plans with a goal of having significant coverage as early as January 2024. Having expansive access and being affordable to the diabetes community is central to achieving our Mission.
Our inclusion in StartUp Health's T1D Moonshot has given us access to a wealth of resources and expertise, and we're grateful for the support of the StartUp Health community. Finally, we're excited to have applied and been selected as a Top 20 finalist in the DCB Innovation Challenge. This is a global competition, and we're honored to be recognized for our work. We look forward to sharing more updates as we move forward.?
Our commitment to making a difference in the lives of people with diabetes remains strong. Thank you for your continued support.
Driving Innovation in Digital Health
Digital health is a transformative field that bridges the gap between technology and healthcare, aiming to provide more efficient and precise care. It is an area that is rapidly evolving, and, by 2032, it is expected that the digital health market will exceed $981 billion. The COVID-19 pandemic has only highlighted the importance of digital health. Telehealth has seen a dramatic increase in usage, and wearable devices are advancing to better track and manage chronic conditions like diabetes. As the world continues to navigate the aftermath of the pandemic and the rise of remote solutions, digital health is becoming essential to providing quality healthcare.
Journey Biosciences is committed to driving innovation in the digital health landscape. We believe that data is the key to better healthcare, and we are passionate about providing valuable data-driven insights for our customers. Our flagship screening, NaviDKD?, provides predictive insights into one's risk for diabetes-related kidney disease (DKD or CKD). Through our digital platform, Compass?, patients and providers can view past and current orders, access test results, and track changes.
Providing this information to patients allows them to feel in control of their health and collaborate with their care team to make smart decisions. For providers, this data allows them to plan more precise treatment strategies for their patients to prevent or delay complications.
However, it is not just about data. Experience is just as important as the data itself. Our goal is to provide easy-to-understand information and actionable insights that help our customers make better informed decisions that improve outcomes for everyone involved. Furthermore, we are dedicated to ensuring accessibility and affordability for patients, understanding the importance of making our solution available to a wide range of individuals. We are committed to collecting feedback and continuously improving our digital experience to maximize the value of our technology.
Digital health is transforming the way we deliver and receive healthcare, and it opens up endless opportunities to enhance patient care, improve efficiency, and broaden access to healthcare services. We firmly believe that NaviDKD and Compass have the potential to make significant contributions to the ongoing innovation in this field, forging a path towards a healthcare landscape that is more personalized, precise, and accessible for all. We look forward to what the future holds.
Journey Biosciences Advances as a Top 20 Finalist in the DCB Innovation Challenge for Diabetes Devices?
We're honored to share that we have been chosen as one of the Top 20 finalists in the Diabetes Center Berne (DCB) Innovation Challenge for Diabetes Devices! This global competition recognizes groundbreaking solutions that are poised to improve the lives of individuals with diabetes.
Participating in the DCB Innovation Challenge not only allows us to showcase NaviDKD to a global audience, but also offers a unique platform for collaboration with like-minded innovators committed to transforming the diabetes landscape.
This competition holds significant importance for us as it aligns perfectly with our core values and ethos—emphasizing innovation, collaboration, and the pursuit of improving the lives of individuals with diabetes. We believe NaviDKD can make a profound and lasting impact on this community, ushering in a future of proactive and preventative care.
We extend our heartfelt appreciation to everyone who showed support for our submission.
领英推荐
Journey Biosciences joins StartUp Health’s T1D Moonshot
We are thrilled to be selected as one of the inaugural companies for the StartUp Health T1D Moonshot Fellowship, generously funded by the Helmsley Charitable Trust. This initiative empowers scientists, entrepreneurs, and innovators dedicated to advancing the prevention, management, and cure of type 1 diabetes (T1D).
Our strong connection to the goals of the T1D Moonshot comes from the real-life experiences of patients under the care of our founder, Dr. Paul J. Beisswenger. As a practicing endocrinologist, he witnessed his patients face serious complications despite their tireless efforts to manage their condition. Determined to make a difference, he dedicated his life to predicting these complications before they became irreversible. Today, we are carrying on his important research and building upon the strong foundation he created.
NaviDKD is the culmination of Dr. Beisswenger's work. As the first predictive screening for people with diabetes, it has the potential to revolutionize the approach to diabetes complications. Given that over a third of people with diabetes develop chronic kidney disease, early detection and intervention are crucial. NaviDKD provides healthcare professionals with an unprecedented ability to predict and prevent kidney disease years before signs or symptoms appear. This brings forth the opportunity to extend life expectancy and enhance the overall quality of life for millions of individuals affected by diabetes.
Our acceptance into the StartUp Health T1D Moonshot Fellowship represents a major milestone for our entire team. It is a resounding validation of the hard work we have poured into the development of NaviDKD. Our commitment to improving the lives of those affected by diabetes is a driving force behind our everyday work, and this fellowship will undoubtedly propel us on our path forward.
We extend our deepest gratitude to StartUp Health and the Helmsley Charitable Trust for granting us this extraordinary opportunity to collaborate, learn, and contribute to the collective effort of enhancing the lives of individuals affected by T1D.?
Recent Events
Earlier this spring, we were able to attend both the JDRF Cleveland TypeOneNation Summit in March, and the ADCES Ohio Symposium in April. It was wonderful to reconnect with so many great people in the diabetes community and to share our work with others who are passionate about improving outcomes for people with diabetes.
Employee Feature
“In my career, I’ve had the opportunity to help build the insulin pump and CGM markets, bringing these technologies to market. What we are doing at Journey Biosciences has the opportunity to make a more significant impact in the lives of people living with diabetes. For me, this is personal. As a daughter of a person with diabetes, I have seen firsthand the positive impact that advances in diabetes care can have. I’m excited to be a part of a pioneering organization using predictive bio markers and AI to enable early identification of those at-risk for DKD which will transform the standard of care.”